cemdisiran + Placebos

Phase 2Withdrawn

0 views this week 0 watching💤 Quiet

Interest: 24/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Atypical Hemolytic Uremic Syndrome

Conditions

Atypical Hemolytic Uremic Syndrome

Trial Timeline

Jan 1, 2021 → Mar 1, 2024

NCT ID

NCT03999840

About cemdisiran + Placebos

cemdisiran + Placebos is a phase 2 stage product being developed by Alnylam Pharmaceuticals for Atypical Hemolytic Uremic Syndrome. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT03999840. Target conditions include Atypical Hemolytic Uremic Syndrome.

What happened to similar drugs?

1 of 8 similar drugs in Atypical Hemolytic Uremic Syndrome were approved

Approved (1) Terminated (0) Active (7)

✅DuloxetineEli LillyApproved

🔄CrovalimabChugai PharmaceuticalPhase 3

🔄Teriparatide 20 mcgEli LillyPhase 3

🔄EculizumabAstraZenecaPhase 3

🔄IptacopanNovartisPhase 3

🔄Iptcaopan 200 mgNovartisPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03999840	Phase 2	Withdrawn	Jan 1, 2021	Mar 1, 2024	Atypical Hemolytic Uremic Syndrome

Competing Products

18 competing products in Atypical Hemolytic Uremic Syndrome

See all competitors

Product	Company	Stage	Hype Score
Crovalimab	Chugai Pharmaceutical	Phase 3	44
Crovalimab	Chugai Pharmaceutical	Phase 3	44
Duloxetine	Eli Lilly	Approved	43
Teriparatide 20 mcg	Eli Lilly	Phase 3	40
Baricitinib	Eli Lilly	Pre-clinical	26
Ravulizumab	AstraZeneca	Pre-clinical	33
Eculizumab	AstraZeneca	Phase 3	40
Iptacopan	Novartis	Phase 3	44
Iptcaopan 200 mg	Novartis	Phase 3	47
Iptacopan	Novartis	Phase 3	47
Ropeginterferon Alfa-2B	PharmaEssentia	Phase 2	42
CCX168	Amgen	Phase 2	27
Tazemetostat + Nivolumab + Ipilimumab	Bristol Myers Squibb	Phase 1/2	39
Cemdisiran	Alnylam Pharmaceuticals	Phase 2	24
Axatilimab + Azacitidine	Incyte	Phase 1/2	36
Gemcitabine + Paxalisib	Pacific Biosciences	Phase 2	32
Apatinib Mesylate	Brain Biotech	Pre-clinical	23
azurin-derived cell-penetrating peptide p28	Brain Biotech	Phase 1	19